OCUL241220C10000
- 0.24
- +0.03+14.29%
Ocular Therapeutix Newsroom
Scotiabank Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $22
Ocular Therapeutix (OCUL) Gets a Buy From Scotiabank
H.C. Wainwright Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Raises Target Price to $15
Ocular Therapeutix Is Maintained at Buy by HC Wainwright & Co.
BofA Securities Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Raises Target Price to $18
TD Cowen Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Raises Target Price to $14
Ocular Therapeutix's Clinical Progress and Strategic Trials Drive Buy Rating
Piper Sandler Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $15
Piper Sandler Remains a Buy on Ocular Therapeutix (OCUL)
Baird Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $17
Ocular Therapeutix Initiated With an Outperform at Scotiabank
Ocular Therapeutix Analyst Ratings
H.C. Wainwright Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $14
BofA Securities Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $15
Buy Rating on Ocular Therapeutix: Accelerated Phase 3 Trial Enrollment and Promising 2025 Outlook
Piper Sandler Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $15
Piper Sandler Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $15
Piper Sandler Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)
Ocular Therapeutix Analyst Ratings
Buy Rating Justified by Ocular Therapeutix's Rapid SOL-1 Trial Progress and Positive FDA Feedback on SOL-R